|
|
|
|
[OctoPlus N.V. (NL) - OctoPlus announces publication of positive Locteron interim Phase IIb data
OctoPlus N.V.('OctoPlus' or 'the Company') (Euronext: OCTO) announces publication of an abstract containing preliminary Locteron Phase IIb clinical results. The abstract was submitted by OctoPlus' licensee Biolex and has been accepted for an oral...
|
|
|
OctoPlus announces 2009 annual results meeting revenue guidance of Euro 19 million
OctoPlus N.V.('OctoPlus' or the 'Company') (Euronext: OCTO), announces today its unaudited annual results for the year ended 31 December 2009, achieving its guidance on revenues of EUR 19 million. At the end of 2008, OctoPlus announced its intention to...
|
|
|
OctoPlus announces publication of positive Locteron interim Phase IIb data
OctoPlus N.V.('OctoPlus' or 'the Company') (Euronext: OCTO) announces publication of an abstract containing preliminary Locteron(,) Phase IIb clinical results. The abstract was submitted by OctoPlus' licensee Biolex and has been accepted for an oral...
|
|
|
Good surgical success rate seen in congenital glaucoma cases after 360 trabeculotomy
NAPLES, Fla.' Approximately 79% of congenital glaucoma cases had surgical success after pseudo-360 primary trabeculotomy, with primary congenital cases fairing best, a study found. The study also found that cases of Sturge-Weber syndrome had...
|
|
|
Vernalis Raising GBP30M to Buy Back EU Rights to Frovatriptan
By Nuala Moran BioWorld International Correspondent LONDON - Vernalis plc is raising 30 million (US$47.1 million) in a placing to buy back the European rights to frovatriptan, the drug which took the company to the brink when it failed to get FDA approval in...
|
|
|
Syracuse woman dying of cancer marries with help of nursing home staff
A couple, whose love had already carried them through decades of sickness and health, fulfilled their dream of becoming man and wife this afternoon.Deborah Cowan, 50, wed longtime companion, Wayne Billington, 60, of Syracuse, at a ceremony organized by staff...
|
|
|
OctoPlus N.V. (NL) - OctoPlus announces that Locteron interim Phase IIb data have been accepted for oral and p
OctoPlus announces that Locteron interim Phase IIb data have been accepted for oral and poster presentations at International Liver Congress in April OctoPlus N.V.('OctoPlus' or 'the Company') (Euronext: OCTO) announces today that its licensee Biolex...
|
|
|
20m fund could help kick-start projects like Nottingham's Medipark
A 20m development fund could prove a vital shot-in-the-arm for stalled schemes aimed at helping to grow Nottingham's science and technology firms.East Midlands Development Agency revealed yesterday that it was launching the Urban Development Fund to invest...
|
|
|
OctoPlus Announces That Locteron Interim Phase IIb Data Have Been Accepted For Oral And Poster Presentations A
OctoPlus N.V.('OctoPlus' or 'the Company') (AMS: OCTO) announces today that its licensee Biolex Therapeutics has been accepted to present interim results from two ongoing Phase IIb studies with Locteron at the 45th Liver Congress on 14 -18 April 2010 in...
|
|
|
OctoPlus Announces That Locteron Interim Phase IIb Data Have Been Accepted for Oral and Poster Presentations a
LEIDEN, THE NETHERLANDS -- (MARKET WIRE) -- 02/10/10 -- OctoPlus N.V.('OctoPlus' or 'the Company') (AMS: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has been accepted to present interim...
|
|
|
OctoPlus announces that Locteron interim Phase IIb data have been accepted for oral and poster presentations a
OctoPlus N.V.('OctoPlus' or 'the Company') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has been accepted to present interim results from two ongoing Phase IIb studies with...
|
